Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study

Porro, G. Bianchi; Lazzaroni, M.; Imbesi, V.; Montrone, F; Santagada, T

doi:10.1016/s1590-8658(00)80821-x

Cited by 55 publications

(44 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Placebo-controlled, randomized trials of PPI therapy indicate NNT of 2-2.5 for secondary prevention of erosive oesophagitis 28 and 7-14 for prevention of NSAID induced peptic ulcer disease in high-risk patients. 29,30 Therefore, the risk ⁄ benefit analysis strongly favours PPI use in a low CDI endemicity setting. Not withstanding the foregoing, PPI or AST prescriptions have been found to be of questionable indication in 41-69% of hospitalized patients, [31][32][33][34][35] indicating that prescribing needs to be more selective and duration of use should be limited to maximize risk benefits.…”

Section: Discussionmentioning

confidence: 99%

Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low‐endemicity, non‐outbreak hospital setting

Dalton

Lye-Maccannell

Henderson

et al. 2009

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low‐endemicity, non‐outbreak hospital setting

Dalton

Lye-Maccannell

Henderson

et al. 2009

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Studies varied in size from 34 63 to 296 participants 62 per arm. Three studies were multicentre and included participants from several countries 59,61,62 and another study was conducted in various centres in North America.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

“…64 Two studies were single centre and both were conducted at the same centre in Italy. 60,63 Five studies were conducted in Europe, two of which also included sites in the UK. 61,62 Publication dates were from 1996 to 2002.…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

“…One study only recruited participants with OA 60 and four studies included adults with RA. 59,[61][62][63] Two studies included adults with other types of arthritis, 59,62 including 138 people (no other details were provided). (Two participants in the trial by Ekstrom and colleagues 59 and 26 participants in the trial by Cullen and colleagues 61 are not described.)…”

Section: Participantsmentioning

confidence: 99%

“…The study by Graham and colleagues 64 does not report details of participants' disease status. Only one study 63 reported the duration of arthritis (mean of 5.1 years in the placebo group and 4.4 years in the pantoprazole group).…”

Section: Participantsmentioning

confidence: 99%

See 2 more Smart Citations

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Brown¹,

Hooper²,

Elliott³

et al. 2006

Health Technol Assess

137

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch ® ) and Current Contents® /Clinical Medicine. NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of car...

show abstract

Current Awareness

2000

Pharmacoepidem. Drug Safe.

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study

Cited by 55 publications

References 18 publications

Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low‐endemicity, non‐outbreak hospital setting

Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low‐endemicity, non‐outbreak hospital setting

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

Current Awareness

Contact Info

Product

Resources

About